Please see below all current urogenital and prostate cancer clinical trials of the Central Coast Cancer Centre.
Name: REAL PRO
Registry-based Study of Enzalutamide vs Abiraterone assessing cognitive function in ELderly patients with Metastatic Castration-Resistant Prostate Cancer.
Principal Investigator: Dr Malmaruha Arasaratnam
Study Coordinator: Bronwyn Raymond
Status: Recruiting
Condition: Prostate Cancer
More information about REAL PRO
Name: SGNLV-005
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for unresectable locally advanced metastatic
solid tumours.
Principal Investigator: Dr Matthew Wong
Study Coordinator: Bronwyn Raymond
Status: Recruiting
Condition: Prostate Cancer
More information about SGNLV-005
Name: CA045-009
A Phase 3 randomised study of neoadjuvant Nivolumab plus NKTR-214, versus Nivolumab alone versus standard of care in particular participants with muscle-invasive bladder cancer (MIBC) who are Cisplatin ineligible.
Principal Investigator: Dr Craig Kukard
Study Coordinator: Michelle Dixon
Status: Recruiting
Condition: Bladder Cancer
More information about CA045-009
Name: CA209-650
A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
Principal Investigator: Dr Craig Kukard
Study Coordinator: Michelle Dixon
Status: Closed
Condition: Prostate Cancer
More information about CA209-650
Name: CA 209-7DX
A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX)
Principal Investigator: Dr Matthew Chan
Study Coordinator: Bronwyn Raymond
Status: Recruiting
Condition: Prostate Cancer
More information about CA 209-7DX
Name: COSMIC-021
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Principal Investigator: Dr Craig Kukard
Study Coordinator: Richard Clayton
Status: Recruiting
Condition: Prostate Cancer
More information about COSMIC-021
Name: DASL HiCaP
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomized phase 3 double-blind, placebo-controlled trial of adding Darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.
Principal Investigator: Dr Craig Kukard
Study Coordinator: Richard Clayton
Status: Recruiting
Condition: Prostate Cancer
More information about DASL HiCaP
More information
For more information about medical oncology clinical trials, please contact the Nurse Unit Manager on 02 4320 9890 or see:
Research and Clinical Trials